HOME >> BIOLOGY >> NEWS
Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer

LOS ANGELES A phase III trial of 1,298 colorectal cancer patients has found that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant improvement in progression-free survival over just irinotecan alone, according to an international team of researchers.

The Erbitux Plus Irinotecan in Colorectal Cancer (EPIC) study looked at survival in metastatic colorectal cancer patients who had already shown resistance to conventional therapies. The research was presented today at the 2007 Annual Meeting of the American Association for Cancer Research.

By the end of the study, a significantly larger number of patients who received the combination of cetuximab, an antibody against the epidermal growth factor and irinotecan, an enzyme-inhibiting cancer drug, survived without their cancers progressing further. The tumor response rate in this group was also significantly higher. The study was sponsored, in part, by Bristol-Myers Squibb and Merck KGaA.

"Patients who received both cetuximab and irinotecan experienced longer periods of time spent, on average, without further progression of the disease," said Alberto F. Sobrero, M.D., of the San Martino Hospital's Department of Medical Oncology in Genoa, Italy. "From a patient perspective, any improvement in progression-free survival, as well as tumor shrinkage, is worthwhile. These data confirm that, despite a moderate increase in side effects, cetuximab is a key therapeutic agent in the optimal treatment of advanced colorectal cancer."

The EPIC trial was designed to study the overall survival in patients treated with both cetuximab and irinotecan, with secondary objectives that include response rate and progression-free survival. Patients eligible in the trial had to have shown resistance to the drug oxaliplatin, a platinum-based therapy commonly used in the treatment of colorectal cancer.

The trial participants, enrolled from cancer centers across Eu
'"/>

Contact: Staci Vernick Goldberg
goldberg@aacr.org
267-646-0616
American Association for Cancer Research
16-Apr-2007


Page: 1 2

Related biology news :

1. Cetuximab increases survival in advanced colorectal cancer patients, study shows
2. New study suggests promising drug combinations for sleeping sickness
3. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
4. Recombination protein dynamics observed with single monomer resolution
5. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
6. New combination treatment induces regression of prostate cancer
7. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
8. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants
9. Pesticide combinations imperil frogs, probably contribute to amphibian decline
10. Study shows combination of immune substances to be safe
11. Immune cell receptors act in combination to regulate attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/3/2020)... ... August 03, 2020 , ... ... new partnership with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 saliva testing ... their laboratory supply chain for more than 10 years. Early in the COVID-19 ...
(Date:7/22/2020)... BARBARA, Calif. (PRWEB) , ... July 21, 2020 ... ... firm driving digital transformation and innovation in technology and compliance, announces a new ... medical device companies must ensure every layer of their technology stack complies with ...
(Date:7/10/2020)... CHURCH, Va. (PRWEB) , ... July 08, 2020 ... ... The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July ... may need a comparability study, but what is the most effective way to ...
Breaking Biology News(10 mins):
(Date:7/7/2020)... ... 06, 2020 , ... R3 International is now offering stem cell therapy for ... cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or with ... form of Alzheimers dementia, and the incidence continues to increase as individuals live longer. ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , a ... 2020, despite many obstacles created as a result of COVID-19. As a provider ... partnered medical practices and medical manufacturers by expanding access to device offerings, technology ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... data insights, today announced that the launch of a new clinical ... data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... develop a vaccine or drug treatment. In an effort to better understand the ... released the world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 ...
Breaking Biology Technology:
Cached News: